FDA Accepts BLA for Biosimilar of Actemra

August 4th 2022

Fresenius Kabi expects to receive FDA approval for its tocilizumab biosimilar in 2023 and is seeking approval in both intravenous and subcutaneous administration.

Pfizer Discontinues Late-Stage Cardiomyopathy Trial

August 4th 2022

Results indicated the trial is unlikely to meet its primary endpoint, the change from baseline in the six-minute walk test at 24 weeks.

CDC Adds Diagnosis Code for Rare Primary Immunodeficiency

August 4th 2022

The new code, effective Oct. 1, 2022, allows APDS to be recognized as an distinct immunological disease.

Keytruda/Lenvima Combo Fails in Liver Cancer Trial

August 4th 2022

This is the second trial in less than a month studying Keytruda that failed to meet endpoints.

Top 4 Drugs to Watch in the Third Quarter

August 3rd 2022

OptumRx profiles four therapies that are expecting FDA decisions in the next few months.